West Pharmaceutical
782 hedge funds and large institutions have $24.5B invested in West Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 96 funds opening new positions, 261 increasing their positions, 306 reducing their positions, and 61 closing their positions.
57% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 61
3% more funds holding
Funds holding: 757 → 782 (+25)
1.65% more ownership
Funds ownership: 92.59% → 94.24% (+1.6%)
3% more call options, than puts
Call options by funds: $80.7M | Put options by funds: $78.2M
5% less capital invested
Capital invested by funds: $25.8B → $24.5B (-$1.28B)
15% less repeat investments, than reductions
Existing positions increased: 261 | Existing positions reduced: 306
56% less funds holding in top 10
Funds holding in top 10: 9 → 4 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$459M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$131M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$99.5M |
| 4 |
APG Asset Management
Amsterdam,
Netherlands
|
+$68.5M |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$64.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$220M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$185M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$135M |
| 4 |
GCM
Gladstone Capital Management
London,
United Kingdom
|
-$81.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$63.6M |
WST Hedge Fund Activity: Q4 2023 in Review
782 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q4 2023, worth a combined $24.5B — down 5% from $25.8B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new WST positions and 61 closed out — a net gain of 35 holders — while 261 added to existing stakes and 306 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $459M. The largest seller was Citadel Advisors, cutting an estimated $220M.
- 782 institutional investors held West Pharmaceutical (WST) as of Q4 2023, up from 757 in Q3 2023.
- Funds reported $24.5B of West Pharmaceutical stock for Q4 2023, down 5% quarter-over-quarter.
- 96 funds opened new West Pharmaceutical positions in Q4 2023 and 61 closed out, a net change of +35 holders.
- The largest West Pharmaceutical buyer in Q4 2023 was Morgan Stanley, an estimated $459M added.
- The largest West Pharmaceutical seller in Q4 2023 was Citadel Advisors, an estimated $220M sold.
Based on aggregated 13F filings for Q4 2023.